Nov 17th 2020

Boston Scientific suspends development of Lotus Edge TAVR platform

In a press release on November 17th, 2020, Boston Scientific announced that it will be discontinuing the Lotus trans-catheter aortic valve platform and will be voluntarily recalling all of the existing Lotus inventory.  According to the press release, the discontinuation of the valve has to do with problems with the delivery system and is not related to the performance of the valve itself.  The REPRISE IV trial for TAVR in intermediate risk patients with severe aortic stenosis will stop immediately.